Rheumatology

Guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practice.

4 Nov, 2022 | 13:42h | UTC

British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practice – Rheumatology

Executive Summary: British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practice – Rheumatology

 

---

Guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids.

4 Nov, 2022 | 13:44h | UTC

British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids – Rheumatology

Executive Summary: British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids – Rheumatology

 

---

Recommendations for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis.

3 Nov, 2022 | 14:01h | UTC

Canadian Rheumatology Association Recommendations for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-associated Uveitis – The Journal of Rheumatology

 

---

SR | Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults.

3 Nov, 2022 | 13:40h | UTC

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults – Cochrane Library

Summary: Treatment of inflammatory conditions of the eye with medications – Cochrane Library

 

---

Narrative review of machine learning in rheumatic and musculoskeletal diseases: biases, goals, and future directions.

3 Nov, 2022 | 13:34h | UTC

Narrative Review of Machine Learning in Rheumatic and Musculoskeletal Diseases for Clinicians and Researchers: Biases, Goals, and Future Directions – The Journal of Rheumatology

 

---

NICE Guideline | Osteoarthritis in over 16s: diagnosis and management.

2 Nov, 2022 | 14:29h | UTC

Osteoarthritis in over 16s: diagnosis and management – National Institute for Health and Care Excellence

 

---

Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study.

2 Nov, 2022 | 14:21h | UTC

Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study – Annals of the Rheumatic Diseases

Commentary: SLE Rates Vary Worldwide and Require Further Study, Study Emphasizes – AJMC

 

---

EULAR points to consider to support people with rheumatic and musculoskeletal diseases in work participation.

2 Nov, 2022 | 14:20h | UTC

2021 EULAR points to consider to support people with rheumatic and musculoskeletal diseases to participate in healthy and sustainable paid work – Annals of the Rheumatic Diseases

News Release: Supporting workers with rheumatic and musculoskeletal diseases – European Alliance of Associations for Rheumatology

 

---

M-A | Collagenase clostridium histolyticum injections vs. percutaneous needle fasciotomy vs. limited fasciectomy in the Dupuytren’s contracture.

1 Nov, 2022 | 12:05h | UTC

Short-term efficacy and adverse effects of collagenase clostridium histolyticum injections, percutaneous needle fasciotomy and limited fasciectomy in the treatment of Dupuytren’s contracture: a network meta-analysis of randomized controlled trials – BMC Musculoskeletal Disorders

 

---

ACR/EULAR remission criteria for rheumatoid arthritis: 2022 Revision.

26 Oct, 2022 | 14:39h | UTC

American College of Rheumatology/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision – Arthritis & Rheumatology

Commentary: New ACR/EULAR Guideline Expands RA Remission Definition – MedPage Today (free registration required)

 

---

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.

26 Oct, 2022 | 14:38h | UTC

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update – Annals of the Rheumatic Diseases

 

---

Optimizing medication use in older adults with rheumatic diseases: deprescribing as an approach when less may be more.

26 Oct, 2022 | 14:33h | UTC

Optimizing Medication Use in Older Adults With Rheumatic Musculoskeletal Diseases: Deprescribing as an Approach When Less May Be More – ACP Open Rheumatology

Related:

Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy – European Heart Journal – Cardiovascular Pharmacotherapy

Deprescribing in Older Adults with Cardiovascular Disease – Journal of the American College of Cardiology

Multimorbidity in Older Adults with Cardiovascular Disease – American College of Cardiology, Latest in Cardiology

Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis – Health Technology Assessment

Antihypertensive Deprescribing in Older Adults: a Practical Guide – Current Hypertension Reports

How-to guide for medication reviews in older adults with cancer: A Young International Society of Geriatric Oncology and Nursing & Allied Health Interest Group initiative – Journal of Geriatric Oncology

Deprescribing in Palliative Cancer Care – Life

Less is More: Deprescribing Medications in Older Adults with Kidney Disease: A Review – Kidney360

Process evaluation of implementation strategies to reduce potentially inappropriate medication prescribing in older population: A scoping review – Research in Social and Administrative Pharmacy

AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review – Gastroenterology

Development of a Metric to Detect and Decrease Low-Value Prescribing in Older Adults – JAMA Network Open

The MedSafer Study—Electronic Decision Support for Deprescribing in Hospitalized Older Adults: A Cluster Randomized Clinical Trial – JAMA Internal Medicine

Quantifying Anticholinergic Burden and Sedative Load in Older Adults with Polypharmacy: A Systematic Review of Risk Scales and Models – Drugs & Aging

Deprescribing in palliative patients with cancer: a concise review of tools and guidelines – Supportive Care in Cancer

Prescribing practices, patterns, and potential harms in patients receiving palliative care: A systematic scoping review – Exploratory Research in Clinical and Social Pharmacy

A narrative review of evidence to guide deprescribing among older adults – Journal of General and Family Medicine

Polypharmacy, inappropriate prescribing, and deprescribing in older people: through a sex and gender lens – The Lancet Health Longevity

Polypharmacy Management in Older Patients – Mayo Clinic Proceedings

Psychopharmacological Treatment in Older People: Avoiding Drug Interactions and Polypharmacy – Deutsches Ärzteblatt international

Eliminating Medication Overload: A National Action Plan – Lown Institute

International Group for Reducing Inappropriate Medication Use & Polypharmacy (IGRIMUP): Position Statement and 10 Recommendations for Action – Drugs & Aging

Common ED Medication Errors: Polypharmacy – emDocs

Current and future perspectives on the management of polypharmacy – BMC Family Practice

Routine deprescribing of chronic medications to combat polypharmacy – Therapeutic Advances in Drug Safety

Polypharmacy—an Upward Trend with Unpredictable Effects – Deutsches Ärzteblatt international

Clinical Consequences of Polypharmacy in Elderly – Expert Opinion on Drug Safety

 

---

RCT | Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis.

25 Oct, 2022 | 13:19h | UTC

Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study – Annals of Rheumatic Diseases

Commentary: Successful retreatment of axSpA flare feasible following ixekizumab withdrawal – medwire News

 

---

Systematic Review | Systemic corticosteroids for radicular and non‐radicular low back pain.

24 Oct, 2022 | 14:03h | UTC

Systemic corticosteroids for radicular and non‐radicular low back pain – Cochrane Library

 

---

Systematic Review | TNF inhibitors for juvenile idiopathic arthritis‐associated uveitis.

21 Oct, 2022 | 12:55h | UTC

Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis‐associated uveitis – Cochrane Library

 

---

Systematic Review | Conservative vs. surgical management for femoro-acetabular impingement.

19 Oct, 2022 | 14:09h | UTC

Conservative vs. Surgical Management for Femoro-Acetabular Impingement: A Systematic Review of Clinical Evidence – Journal of Clinical Medicine

Related:

Arthroscopic hip surgery compared with personalised hip therapy in people over 16 years old with femoroacetabular impingement syndrome: UK FASHIoN RCT – Health Technology Assessment

Arthroscopic hip surgery compared with physiotherapy and activity modification for the treatment of symptomatic femoroacetabular impingement: multicentre randomised controlled trial – The BMJ

 

---

RCT | Allopurinol does not improve outcomes in patients with ischemic heart disease without previous gout.

13 Oct, 2022 | 13:53h | UTC

Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial – The Lancet

Invited Commentary: Xanthine oxidase inhibition for cardiovascular disease prevention – The Lancet

Related: [News release – not published yet] #ESCCongress – RCT | Allopurinol does not improve cardiovascular outcomes in ischemic heart disease patients.

 

Commentary on Twitter

Despite favorable effects on surrogate endpoints in smaller trials, in an RCT trial of 5,721 pts with CAD, allopurinol did not significantly improve cardiovascular prognosis compared to placebo https://t.co/ITW4HAwI2K @TheLancet pic.twitter.com/EggHM8flle

— Pradeep Natarajan (@pnatarajanmd) October 7, 2022

Under a Creative Commons Attribution (CC BY 4.0) License

 

---

RCT | Intravenous immune globulin reduces disease activity in dermatomyositis.

6 Oct, 2022 | 13:48h | UTC

Trial of Intravenous Immune Globulin in Dermatomyositis – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries:

NEJM: trial of IVIG for autoimmune disorder dermatomyositis – MedicalResearch.com

IV Immune Globulin Bests Placebo for Dermatomyositis – Drugs.com

 

---

M-A | Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis.

6 Oct, 2022 | 13:37h | UTC

Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis – BMC Rheumatology

 

---

RCTs | Effect of Roflumilast cream vs. vehicle cream on chronic plaque psoriasis.

22 Sep, 2022 | 13:06h | UTC

Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials – JAMA (free for a limited period)

Editorial: Roflumilast for Chronic Plaque Psoriasis – JAMA

Commentary: Study Suggests Roflumilast May Be Effective As Treatment For Plaque Psoriasis – HCPLive

 

Commentary on Twitter

Roflumilast cream resulted in better chronic plaque psoriasis clinical status compared with vehicle cream at 8 weeks; further research is needed to compare efficacy with other active treatments and to assess longer-term efficacy and safety. https://t.co/DyGNNjr5ea #Research pic.twitter.com/QnMcChnht6

— JAMA (@JAMA_current) September 21, 2022

 

---

RCT | Effect of Tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy.

22 Sep, 2022 | 13:06h | UTC

Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Tocilizumab as a Novel Therapy for Steroid-Dependent Polymyalgia Rheumatica – JAMA (free for a limited period)

Video Editor’s Note: Tocilizumab and Disease Activity in Patients With Polymyalgia Rheumatica Receiving Glucocorticoid Therapy – JAMA

 

---

RCT | Deucravacitinib vs. placebo and Apremilast in moderate to severe plaque psoriasis.

20 Sep, 2022 | 13:16h | UTC

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial – Journal of the American Academy of Dermatology

 

---

RCT | Methotrexate may increase response rates in patients with uncontrolled gout receiving Pegloticase.

19 Sep, 2022 | 12:38h | UTC

A Randomized Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR RCT): Primary Efficacy and Safety Findings – Arthritis & Rheumatology

Commentary: Data Now Out for Pegloticase-MTX Combo Gout Treatment – MedPage Today (free registration required)

 

---

RCT | Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumor necrosis factor inhibitor therapy.

19 Sep, 2022 | 12:35h | UTC

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study – Annals of Rheumatic Diseases

 

---

Study finds a higher complication rate after acute coronary syndrome in patients with rheumatic immune‐mediated inflammatory diseases.

15 Sep, 2022 | 13:01h | UTC

Outcomes Following Acute Coronary Syndrome in Patients With and Without Rheumatic Immune‐Mediated Inflammatory Diseases – Journal of the American Heart Association

News Release: Study finds higher complication rate after heart attack in people with autoimmune disease – American Heart Association

 

---